5 months ago
Real world data of 1297 cases of Axicabtagene Ciloleucel DLBCL Treated in the United States Axi cel real world research Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric ant...
5 months ago
Overview of Axicabtagene Ciloleucel Approval What is Axicabtagene Ciloleucel Axicabtagene Ciloleucel is a type of chimeric antigen receptor (CAR) T-cell therapy, a cutting-edge form of immunotherap...
5 months ago
Yescarta FDA Label Updated to Include Overall Survival Data for Large B-Cell Lymphoma In early April 2024, the U.S. Food and Drug Administration (FDA) approved an updated prescribing information fo...
5 months ago
October 17, 2022 Yescarta EMA Approved for Second-line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) and Advanced B-cell Lymphoma (HGBL) On October 17, 2022, exciting news arrived from the Eur...
5 months ago
Nature Medicine | **New Hope! Chinese Medical Team Makes Breakthrough in Gastric Adenocarcinoma Treatment** Nature Medicine In the medical field, unresectable advanced or metastatic gastric or g...
5 months ago
Yescarta FDA Approval for Second-Line Treatment of Large B-Cell Lymphoma on April 1, 2022 On April 1, 2022, Kite, a U.S. company, announced that the U.S. Food and Drug Administration (FDA) has appr...
5 months ago
Yescarta CAR-T Cell Therapy is Safe and Effective for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) Patients: 3-Year Follow-Up Analysis from the ZUMA-5 Study Yescarta (Axicabtagene cilol...
5 months ago
🌟 Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors 🌟 Gastrointestinal Tumor Chinese biotech company CARsgen Ther...
5 months ago
Axicabtagene Ciloleucel (Yescarta) Approved: Bringing New Hope to Patients with Relapsed or Refractory Lymphoma I. Introduction Yescarta (Axicabtagene Ciloleucel, Chinese name: 阿基仑赛, Chinese tr...
5 months ago
Study on the Therapeutic Effect of Mantle Cell Lymphoma CAR-T Combined with Ibrutinib For patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), the efficacy of CD19-targeted CAR-T cel...
5 months ago
On May 27, 2022, Kymriah FDA Approved it For the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) Follicular lymphoma (FL) is the most common indolent lymphoma and the second most commo...
5 months ago
On May 4, 2022, Kymriah EMA Approval for the Treatment of Follicular Lymphoma (FL) On May 4, 2022 (Basel), Novartis announced that the European Commission has expanded the approval of Kymriah (tisa...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
